La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Gross offering proceeds will be
The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-197092), including a base
prospectus, which was declared effective by the
This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties, such as the risk that the conditions to the closing of the offering will not be satisfied. All forward-looking statements are based upon information available to La Jolla on the date the statements are first published. La Jolla undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.